Fig. 5

Manipulation of the sphingolipid rheostat enzymes or ceramide de novo synthesis alters cell death in the hai1a^fr26 mutant.

a Schematic of sphingolipid rheostat showing inhibition of ceramidases with ceranib-2, inhibition of sphingosine kinases with MPA08 or SKI-II, inhibition of S1P phosphatase with a MO targeting sgpp1, inhibition of serine palmitoyltransferase with myriocin or SPT-IN-1 and sphingomyelinases with desipramine, and MOs targeting cers5 and cers6 at the level of de novo synthesis and salvage from sphingosine. b Quantification of aCasp3-positive cells in the tail fins of 4 dpf embryos upon DMSO or ceranib-2 treatment, normalised to fin area. c Quantification of aCasp3-positive cells in the tail fins of control or sgpp1 MO-injected 4 dpf embryos, normalised to fin area. d Quantification of aCasp3-positive cells in the tail fins of 4 dpf embryos upon DMSO, myriocin, or desipramine treatment, normalised to fin area. e Quantification of aCasp3-positive cells in the tail fins of control or cers5 alone, cers6 alone, or both cers5 and cers6 MO-injected 4 dpf embryos, normalised to fin area. For all graphs, means were compared using one-way ANOVA with post-hoc Tukey’s multiple comparison test. N = number of biological replicates, n = number of fish per condition.